Filing Details
- Accession Number:
- 0001062993-24-020910
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-19 16:19:34
- Reporting Period:
- 2024-12-18
- Accepted Time:
- 2024-12-19 16:19:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1840233 | Xilio Therapeutics Inc. | XLO | Biological Products, (No Disgnostic Substances) (2836) | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 882095 | Gilead Sciences, Inc. | 333 Lakeside Drive Foster City CA 94404 | No | No | Yes | No |
Transaction Summary
| Purchased: | 1,759,978 shares | Avg. Price: $1.04 | Total Value: $1,830,377.12 |
| Number of Shares After Transactions: | 9,105,451 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-12-18 | 1,759,978 | $1.04 | 9,105,451 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Prefunded Warrants (right to buy) | Acquisiton | 2024-12-18 | 6,092,816 | $1.04 | 6,092,816 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 9,975,266 | No | 4 | P | Direct |
Footnotes
- The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.